Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4942063 | 1.00 | ACE (0.32) | ACEMMP1MMP2MMP3MMP7 | |
| SCHEMBL12469622 | 0.84 | — | — | |
| SCHEMBL22518860 | 0.82 | — | — | |
| SCHEMBL22518861 | 0.82 | — | — | |
| SCHEMBL28706954 | 0.80 | ALDH1A1 (0.32) | ACE | |
| SCHEMBL28706955 | 0.80 | ALDH1A1 (0.32) | ACE | |
| SCHEMBL22648657 | 0.80 | MMP2 (0.41) | MMP1MMP2MMP3MMP7 | |
| SCHEMBL201027 | 0.80 | MMP2 (0.41) | MMP1MMP2MMP3MMP7 | |
| SCHEMBL31216660 | 0.80 | TSHR (0.40) | ACEMMP1MMP2MMP3MMP7 | |
| SCHEMBL16774529 | 0.77 | LMNA (0.42) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024220532-A1 | PYRROLIDINE KRAS INHIBITORS | INCYTE CORPORATION (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240239771-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | TAXIS PHARMACEUTICALS, INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2024131827-A1 | KRAS G12D INHIBITORS AND USES THEREOF | 上海和誉生物医药科技有限公司 | 2024-06-27 | — | — | WO | disclosed |
| EP-4332105-A1 | PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-20230416199-A1 | INHIBITORS OF AMINO ACID TRANSPORT | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4291563-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20220281893-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2022087630-A1 | INHIBITORS OF AMINO ACID TRANSPORT | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-108024992-A | Aryl, Heteroaryl and Heterocyclic Compounds for the Treatment of Medical Disorders | 艾其林医药公司 | 2018-05-11 | — | — | CN | disclosed |
| EP-3268046-A1 | CONJUGATES FOR TREATING DISEASES | Endocyte, Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2017172930-A1 | PBD CONJUGATES FOR TREATING DISEASES | ENDOCYTE, INC. (US) | 2017-10-05 | — | — | WO | disclosed |
| CN-106166160-A | For treating the compositions of HCV | 吉利德制药有限责任公司 | 2016-11-30 | — | — | CN | disclosed |
| WO-2016148674-A1 | CONJUGATES FOR TREATING DISEASES | ENDOCYTE, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| CN-104244945-B | METHODS FOR TREATING HCV | 吉利德制药有限责任公司 | 2016-08-31 | — | — | CN | disclosed |
| CN-104244945-A | METHODS FOR TREATING HCV | GILEAD SCIENCES INC | 2014-12-24 | — | — | CN | disclosed |
| CN-100418525-C | Proline derivatives having affinity for the calcium channel alpha-2-delta subunit | PFIZER (US) | 2008-09-17 | — | — | CN | disclosed |
| US-20070129381-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE ESTER DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-06-07 | — | — | US | disclosed |
| CN-1711081-A | Proline derivatives having affinity for the alpha-2-delta subunit of calcium channels | PFIZER (US) | 2005-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129381-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE ESTER DERIVATIVES | OXTR, GPR6, CNR1 | ACE 3631/4885MMP1 4211/4885MMP2 3461/4885 |
| US-20220281893-A1 | TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | OXA1L, CACNA1I, GRIK5 | ACE 2222/4885MMP1 4248/4885MMP2 1704/4885 |
| US-20230416199-A1 | INHIBITORS OF AMINO ACID TRANSPORT | SLC1A5, SLC7A1, SLC7A5 | ACE 1294/4885MMP1 3183/4885MMP2 2208/4885 |
| US-20240239771-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | ACE 927/4885MMP1 2033/4885MMP2 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.